Edition:
India

Antares Pharma Inc (ATRS.OQ)

ATRS.OQ on NASDAQ Stock Exchange Capital Market

3.43USD
1:30am IST
Change (% chg)

$-0.03 (-0.87%)
Prev Close
$3.46
Open
$3.46
Day's High
$3.49
Day's Low
$3.43
Volume
94,568
Avg. Vol
277,351
52-wk High
$3.96
52-wk Low
$2.54

Latest Key Developments (Source: Significant Developments)

Antares Pharma Reports Second Quarter 2019 Operating And Financial Results
Tuesday, 6 Aug 2019 

Aug 6 (Reuters) - Antares Pharma Inc ::ANTARES PHARMA REPORTS SECOND QUARTER 2019 OPERATING AND FINANCIAL RESULTS.Q2 LOSS PER SHARE $0.01.Q2 REVENUE ROSE 101 PERCENT TO $28.4 MILLION.Q2 REVENUE ESTIMATE $22.5 MILLION -- REFINITIV IBES DATA.Q2 EARNINGS PER SHARE ESTIMATE $-0.04 -- REFINITIV IBES DATA.SEES FY 2019 REVENUE $100 MILLION TO $110 MILLION.INCREASES FULL YEAR 2019 REVENUE GUIDANCE TO A RANGE OF $100.0 TO $110.0 MILLION.AT JUNE 30, 2019, CASH AND CASH EQUIVALENTS WERE $40.2 MILLION COMPARED TO $27.9 MILLION AT DECEMBER 31, 2018..FY2019 REVENUE VIEW $101.9 MILLION -- REFINITIV IBES DATA.  Full Article

Antares Pharma Q3 Loss Per Share $0.01
Tuesday, 6 Nov 2018 

Antares Pharma Inc ::ANTARES PHARMA REPORTS THIRD QUARTER 2018 OPERATING AND FINANCIAL RESULTS.Q3 LOSS PER SHARE $0.01.Q3 REVENUE $17.9 MILLION VERSUS I/B/E/S VIEW $15 MILLION.Q3 EARNINGS PER SHARE VIEW $-0.02 -- THOMSON REUTERS I/B/E/S.  Full Article

Antares Pharma Q4 Loss Per Share $0.02
Tuesday, 13 Mar 2018 

March 13 (Reuters) - Antares Pharma Inc ::ANTARES PHARMA REPORTS FOURTH QUARTER AND FULL YEAR 2017 OPERATING AND FINANCIAL RESULTS.Q4 LOSS PER SHARE $0.02.Q4 EARNINGS PER SHARE VIEW $-0.03 -- THOMSON REUTERS I/B/E/S.ANTARES PHARMA - QTRLY TOTAL REVENUE $14.0 MILLION VERSUS $14.2 MILLION.  Full Article

AMAG Gets FDA Approval Of Makena Subcutaneous Auto-Injector
Thursday, 15 Feb 2018 

Feb 14 (Reuters) - Amag Pharmaceuticals Inc ::AMAG PHARMACEUTICALS ANNOUNCES FDA APPROVAL OF MAKENA® (HYDROXYPROGESTERONE CAPROATE INJECTION) SUBCUTANEOUS AUTO-INJECTOR TO REDUCE THE RISK OF PRETERM BIRTH IN CERTAIN AT-RISK WOMEN.AMAG PHARMACEUTICALS - EXPECTS TO FILE A NEW DRUG APPLICATION THIS QUARTER FOR A NEW CHEMICAL ENTITY (BREMELANOTIDE) ​.AMAG PHARMACEUTICALS INC - ‍EXPECTS SUBCUTANEOUS AUTO-INJECTOR TO BE AVAILABLE IN SECOND HALF OF MARCH​.AMAG PHARMACEUTICALS INC - WILL CONTINUE TO OFFER IM FORMULATION OF MAKENA IN BOTH SINGLE-DOSE AND MULTI-DOSE VIALS​.AMAG PHARMACEUTICALS INC - ‍MAKEN'S 7-YEAR ORPHAN DRUG EXCLUSIVITY EXPIRED EARLIER THIS MONTH​.AMAG PHARMACEUTICALS - ANNOUNCES FDA APPROVAL OF MAKENA (HYDROXYPROGESTERONE CAPROATE INJECTION) SUBCUTANEOUS AUTO-INJECTOR ‍​.  Full Article

Antares Pharma Provides Xyosted Regulatory Update
Tuesday, 16 Jan 2018 

Jan 16 (Reuters) - Antares Pharma Inc ::ANTARES PHARMA PROVIDES XYOSTED™ REGULATORY UPDATE.ANTARES PHARMA INC - TYPE A MEETING HAS BEEN SCHEDULED WITH U.S. FOOD AND DRUG ADMINISTRATION ON FEBRUARY 21, 2018 FOR XYOSTED.ANTARES PHARMA - REQUEST FOR MEETING WAS IN RESPONSE TO COMPLETE RESPONSE LETTER RECEIVED BY ANTARES REGARDING NEW DRUG APPLICATION FOR XYOSTED.  Full Article

Antares Pharma Q3 loss per share $0.03
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - Antares Pharma Inc :Antares Pharma reports third quarter 2017 operating and financial results.Q3 loss per share $0.03.Q3 revenue $15.1 million versus I/B/E/S view $14 million.Q3 earnings per share view $-0.03 -- Thomson Reuters I/B/E/S.Antares Pharma - ‍at September 30, 2017, cash, cash equivalents and short-term investments were $37.4 million compared to $27.7 million at December 31, 2016​.  Full Article

No consensus analysis data available.